Today’s cyclodextrin research highlights a promising new therapy for inflammation-related diseases and oxidative damage. Researchers have presented a new anti-inflammatory and antioxidant nanoparticle, LCD, which aims to protect against severe burn-induced intestinal injury. With traditional methods showing limitations, the application of nanoparticles like LCD could offer a much-needed protective strategy for the intestinal barrier.
Galectins are an evolutionarily conserved family of glycan-binding proteins with multifunctional roles in immunity. These proteins often shuttle between different intracellular compartments (nucleus, cytoplasm, and organelles) and are released to the extracellular milieu, where they acquire different roles in response to diverse microenvironmental stimuli, including hypoxia, nutrient availability, intracellular and extracellular pH, cytokine milieu and the presence of proinflammatory or immunosuppressive signals. Within the immune system, galectins can elicit a wide array of important functions that tailor both innate and adaptive responses, playing key roles in shaping the choreography of immune cells in health and disease. Interestingly, the same galectin can function as a cytokine, chemokine, cell adhesion molecule, immune checkpoint molecule, danger-associated molecular pattern, or growth factor depending on different cellular programs, including activation, differentiation, and trafficking, or during pathologic conditions, such as pathogen invasion, autoimmune inflammation, fibrosis and cancer. Learn more from the great white paper by Gabriel Rabinovich!
DSM proposes to use oligosaccharide compositions as microbiome metabolic therapies for treating inflammatory lung diseases and disorders, such as chronic obstructive pulmonary disease (COPD) and asthma. See the original patent on Espacenet:
Mannosylated glycans impair normal T-cell development. Gabriel Rabinovich, Salomé S. Pinho et al. discovered stage-specific glycome compositions during T-cell development in human and murine thymocytes, as well as dynamic alterations. In conclusion, mannosylated thymocytes lead to a dysregulation in T-cell development that is associated with inflammation susceptibility.
today’s cyclodextrin: it makes me particularly happy to post about the recent success of Heegon Kim and RENATUS, as I have known and admired Heegon’s work for a while and we share a vision of the importance of developing CD-based therapies. Renatus develops gamma-cyclodextrin-based polymer to prevent or treat cholesterol metabolism-related diseases to minimize cell membrane cholesterol extraction, thus exhibiting an excellent anti-inflammatory effect by causing no cytotoxicity and hemolytic activity, making intracellular cholesterol metabolism and release easy and effectively inhibiting the release of IL-1β, MCP-1, and TNF-α.
Have you known that Arivin Therapeutics uses cyclodextrin for targeting bacterial virulence as a novel treatment against AMR infections? Among their MoA claims, the following are listed: – Targeting virulence factors is effective, also against extensively resistant isolates – Targeting virulence avoids rapid resistance – Direct reduction in inflammatory responses – Potentiates the function of antibiotics Also, there is a spectacular video about how CDs develop their effect as antibacterials.
